Extracellular vesicles from equine mesenchymal stem cells decrease inflammation markers in chondrocytes in vitro.
Authors: Arévalo-Turrubiarte Magdalena, Baratta Mario, Ponti Giovanna, Chiaradia Elisabetta, Martignani Eugenio
Journal: Equine veterinary journal
Summary
# Editorial Summary Mesenchymal stem cell therapy has gained traction in equine practice, but the therapeutic action may not depend solely on the cells themselves—the extracellular vesicles (EVs) they release appear to carry significant regenerative potential. Arévalo-Turrubiarte and colleagues isolated EVs from equine bone marrow, adipose tissue, and synovial fluid MSCs, characterising their size, concentration, morphology, and CD9 expression before testing their effects on chondrocytes exposed to inflammatory cytokines (interleukin-1β and tumour necrosis factor-alpha). EVs derived from bone marrow MSCs substantially reduced metalloproteinase-13 (MMP-13) gene expression in inflamed chondrocytes, whereas synovial fluid-derived EVs showed less pronounced effects; critically, MMP-13 is a key collagenase implicated in cartilage matrix degradation. These findings suggest that EV therapy could work synergistically with conventional joint treatments by dampening the catabolic cascade that drives degenerative joint disease, though further investigation into EV content and in vivo efficacy is needed before clinical application. For practitioners managing equine joint pathology, this work provides a mechanistic rationale for considering cell-derived EV products as potential adjuvant therapies alongside traditional anti-inflammatory and joint-protective strategies.
Read the full abstract on PubMed
Practical Takeaways
- •MSC-derived extracellular vesicles show promise as an adjuvant therapy for equine joint disease by reducing cartilage-degrading enzymes in inflamed tissue
- •Bone marrow-derived EVs may be a practical source material for developing regenerative treatments for articular pathologies in horses
- •Further clinical trials are needed to translate these in vitro findings into therapeutic protocols for joint conditions
Key Findings
- •Extracellular vesicles (EVs) isolated from equine bone marrow mesenchymal stem cells reduced metalloproteinase-13 gene expression in inflamed chondrocytes in vitro
- •EVs from bone marrow and synovial fluid MSCs did not differ significantly in size and concentration across tissue sources
- •EV particles expressed CD9 marker and demonstrated round-like morphology on transmission electron microscopy
- •MSC-derived EVs reduced inflammation markers in chondrocytes treated with pro-inflammatory cytokines (IL-1β and TNF-α)